Daniel Krivoy, MD
Glaucoma Specialist · Culver City, CANPI 1679531974
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $21,525 of the $29,196 with a category attached, or 73.7%. AbbVie accounts for 73.0% of it on its own, with 23 other manufacturers making up the rest.
Across 159 payments — averaging $183.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$21K
- Ivantis, Inc$4K
- Alcon$909
- Alcon Research LLC$550
- NEW World Medical,inc.$419
- Glaukos Corporation$339
- plus $2K from 18 others
Across 28 payments — averaging $5062.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$109K
- Topcon Healthcare Solutions, Inc.$33K
What the payments were for
- Consulting fees$21,52574%
- Speaking & faculty fees$1000%
- Travel & lodging$1,2084%
- Food & beverage$6,23821%
- Education$800%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 87 | $21,316 |
| Ivantis, Inc | 10 | $4,081 |
| Alcon | 15 | $909 |
| Alcon Research LLC | 1 | $550 |
| NEW World Medical,inc. | 6 | $419 |
| Glaukos Corporation | 2 | $339 |
| Bausch & Lomb Americas Inc. | 6 | $274 |
| Ocular Therapeutix, Inc. | 5 | $234 |
| Tarsus Pharmaceuticals, Inc. | 2 | $211 |
| Nova Eye, Inc. | 1 | $139 |
| Carl Zeiss Meditec USA, Inc. | 3 | $136 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $118 |
| Rxsight Inc | 4 | $99 |
| Novartis | 4 | $97 |
| Amgen | 2 | $42 |
| Dompe US, Inc. | 2 | $41 |
| Sun Pharmaceutical Industries Inc. | 1 | $32 |
| Rayner Intraocular Lenses Limited | 1 | $28 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| Oyster Point Pharma, Inc. | 1 | $24 |
| Sight Sciences, Inc. | 1 | $22 |
| Biotissue Holdings Inc. | 1 | $22 |
| Kala Pharmaceuticals, Inc. | 1 | $21 |
| Akorn Operating Company LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$11,600
- XEN$7,721
- Hydrus Microstent$4,090
- Constellation$242
- iStent inject W$202
- Kahook Dual Blade$163
- Clearpath$163
- Ahmed Glaucoma Valve$163
- Streamline$163
- iStent Trabecular Micro-Bypass System Model iS3$137
- Unity$131
- XDEMVY$120
- LOTEMAX$118
- VYZULTA$110
How this compares
$29,196 in reported general payments places this provider in the 75th percentile of 64 glaucoma specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 93 | $77,210 |
| RocklatanNetarsudil Mesylat/Latanoprost | 111 | $46,753 |
| VyzultaLatanoprostene Bunod | 124 | $45,694 |
| LumiganBimatoprost | 126 | $44,042 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 141 | $29,217 |
| Alphagan PBrimonidine Tartrate | 79 | $28,666 |
| AzoptBrinzolamide | 50 | $25,579 |
| RhopressaNetarsudil Mesylate | 69 | $24,583 |
| ZioptanTafluprost/Pf | 78 | $22,086 |
| Prednisolone Acetate | 343 | $17,317 |
| CombiganBrimonidine Tartrate/Timolol | 62 | $17,295 |
| Brinzolamide | 89 | $13,743 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 75 | $13,233 |
| MieboPerfluorohexyloctane/Pf | 17 | $12,651 |
| Cyclosporine | 46 | $11,726 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $21,316 | $167,213360 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Miebo | $274 | $58,345141 claims |
| AlconSimbrinza, Azopt | $909 | $54,796191 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 64 glaucoma specialist providers in California.
Other glaucoma specialist in Culver City
- Valentina LozanoCulver City$51K
- Jason BacharachPetaluma$1.7M
- Billy PanBeverly Hills$250K
- Jacob BrubakerSacramento$229K
- Felise May BarteSanta Clara$121K
- Houman VosoghiWestlake Village$119K
- Robert ChangStanford$105K
- Sophia WangStanford$77K
- Jeffrey GoldbergStanford$57K
- Sameh MosaedIrvine$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.